Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04684589 · ClinicalTrials.gov registry record · Phase 2
Effect of PDE5 Inhibition on Adipose Metabolism in Humans
A Phase 2 study, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 89
- Enrollment target
NCT04684589 is a Phase 2 study that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 89 participants.
The verdict
NCT04684589, a Phase 2 study, has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 89 participants
- Enrollment target
Study Summary
This is a randomized, double-blinded, placebo-controlled study of the effects of PDE5 inhibition with tadalafil on adipose tissue in obese individuals. Adipose metabolism will be measured using magnetic resonance imaging (MRI) scans and by aspirating a small amount of adipose to measure gene expression.
Interventions
- DRUG Placebo
- DRUG Tadalafil 20 MG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2021-03-16 |
| Est. Completion | 2025-06-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04684589
The ClinicalTrials.gov registry entry for NCT04684589 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 89 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04684589 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04684589 about?
NCT04684589 is a clinical study titled "Effect of PDE5 Inhibition on Adipose Metabolism in Humans". This is a randomized, double-blinded, placebo-controlled study of the effects of PDE5 inhibition with tadalafil on adipose tissue in obese individuals. Adipose metabolism will be measured using magnetic resonance imaging (MRI) scans and by aspirating a small amount of adipose to measure gene express...
What is the current status of trial NCT04684589?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 89 participants. The study started on 2021-03-16. Estimated completion is 2025-06-24.
What interventions are being tested in trial NCT04684589?
The interventions under investigation include: Placebo (DRUG), Tadalafil 20 MG (DRUG).
Who is sponsoring clinical trial NCT04684589?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.